BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15679766)

  • 1. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
    Graham DY; Opekun AR; Belson G; El-Zimaity HM; Carlson MR
    Aliment Pharmacol Ther; 2005 Jan; 21(2):165-8. PubMed ID: 15679766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.
    de Boer WA; van Etten RJ; Schneeberger PM; Tytgat GN
    Am J Gastroenterol; 2000 Mar; 95(3):641-5. PubMed ID: 10710051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
    Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
    Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection.
    Cammarota G; Cannizzaro O; Cianci R; Gasbarrini A; Pirozzi G; Gasbarrini G
    Hepatogastroenterology; 2000; 47(34):1176-9. PubMed ID: 11020908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
    Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
    Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
    Lerang F; Moum B; Ragnhildstveit E; Sandvei PK; Tolås P; Whist JE; Henriksen M; Haug JB; Berge T
    Am J Gastroenterol; 1998 Feb; 93(2):212-6. PubMed ID: 9468244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
    Gisbert JP; Fuentes J; Carpio D; Tito L; Guardiola J; Tomas A; Olivares D; Calvet X
    Aliment Pharmacol Ther; 2005 May; 21(10):1249-53. PubMed ID: 15882246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin for the cure of Helicobacter pylori infection.
    Di Mario F; Dal Bó N; Grassi SA; Rugge M; Cassaro M; Donisi PM; Vianello F; Kusstatscher S; Salandin S; Grasso GA; Ferrana M; Battaglia G
    Am J Gastroenterol; 1996 Feb; 91(2):264-7. PubMed ID: 8607490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
    al-Assi MT; Ramirez FC; Lew GM; Genta RM; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1203-5. PubMed ID: 8053435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
    Dore MP; Graham DY; Mele R; Marras L; Nieddu S; Manca A; Realdi G
    Am J Gastroenterol; 2002 Apr; 97(4):857-60. PubMed ID: 12003419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid suppression with ranitidine plus oral triple therapy improves ulcer healing but not Helicobacter pylori eradication.
    Magalhaes AF; Macedo C; Hauck JR; Carvalhaes A; De Nucci G; Magna LA; Pedrazzoli J
    Hepatogastroenterology; 1998; 45(24):2161-4. PubMed ID: 9951885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
    Marko D; Calvet X; Ducons J; Guardiola J; Tito L; Bory F;
    Helicobacter; 2005 Feb; 10(1):22-32. PubMed ID: 15691312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.